Health Care/Hospital
95 years of protecting Singapore: AIA launches AIA Protect 3 to empower the workforce and close critical illness gap
Exclusive to AIA individual and corporate customers and their families, AIA Protect 3 provides multi-stage coverage for cancer, heart attack and stroke — the three most common critical illnesses in Singapore — as a starter or practical critical illness plan SINGAPORE, May 19, 2026 /PRNewswire/ -...
2026-05-19 11:11
963
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
NANJING, China, May 18, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of Chi...
2026-05-19 09:35
2455
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-05-19 08:00
2793
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza * Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro Bio...
2026-05-19 08:00
2384
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose reached with no dose-limiting toxicities observed. * TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia ...
2026-05-19 05:00
2748
Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing
NORWALK, Conn., May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC...
2026-05-19 01:03
2193
Millions of 'pandemic pets' are reaching midlife, but owners could miss a crucial opportunity to improve their pet's healthspan
* New global research commissioned by ROYAL CANIN® reveals disconnect in how owners understand their pet's ageing with over a third surveyed (38%) believing nothing can be done about it*, while over half (55%) of those surveyed avoid thinking or talking about their pets ageing because it feels ...
2026-05-18 22:09
2935
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...
2026-05-18 22:00
2951
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...
2026-05-18 21:15
3616
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...
2026-05-18 21:00
2746
MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region AMMAN, Jordan and RIYADH, Saudi Arabia, May 18, 2026 /PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings s...
2026-05-18 20:39
2040
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic...
2026-05-18 19:00
2332
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
* Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 * Current treatments are limited by suboptimal disease control and treatment-related complications3,4 * Asedebart (Lu AG13...
2026-05-18 17:10
2331
PAIR and Cambridge NeuroWorks launch new online neuroscience seminar series in May 2026
HONG KONG, May 18, 2026 /PRNewswire/ -- The PolyU Academy for Interdisciplinary
Research (PAIR) of The Hong Kong Polytechnic University has joined forces with
Cambridge NeuroWorks,
2026-05-18 16:00
2579
PolyU collaborates with global scholars and experts to promote modern healthcare and wellness
Close to 100 participants experience Taichi and Qigong HONG KONG, May 18, 2026 /PRNewswire/ -- The Research Centre for Chinese Medicine Innovation (RCMI) of The Hong Kong Polytechnic University (PolyU) hosted the "Symposium on Martial Arts: Bridging Art and Science" and two "Health Cultivation W...
2026-05-18 14:53
2935
Johnson & Johnson Launches 'Gut Tunnel' Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD
New data presented at Digestive Disease Week 2026 reinforces endoscopic remission as being associated with long-term patient outcomes,[1],[2] yet more than 60% of people with IBD have not heard of this key treatment goal.[3],[4] Anchoring World IBD Day, the interactive Gut Tunnel installation...
2026-05-18 10:00
2530
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical compan...
2026-05-18 08:03
2095
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), whic...
2026-05-18 08:00
1674
LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partn...
2026-05-18 08:00
1508
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
A nanosized extract of the plant thylakoid grana — the molecular engine behind photosynthesis — is transplanted into the eye's corneal cells, producing a key protective molecule when exposed to ambient light, opening a new front against dry eye disease SINGAPORE, May 15, 2026 /PRNewswire/ -- Wha...
2026-05-16 11:14
5234
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
8049
